UAE Creates First AI-Designed Drug in Under 12 Months

Creating a new medicine typically costs up to $2.6 billion and takes over a decade, with early discovery alone consuming 4.5 years. But a team in the United Arab Emirates just did it in under 12 months using artificial intelligence.

Insilico Medicine announced the nomination of ISM0387, a potential treatment for glioblastoma, an aggressive form of brain cancer. The entire development journey happened locally in Abu Dhabi, marking the first drug candidate ever discovered and developed entirely within the UAE.

The achievement represents more than just speed. It signals that cutting-edge pharmaceutical research is no longer limited to a handful of wealthy nations with decades of infrastructure.

The UAE team consisted of just four specialists: two computational chemists, one medicinal chemist, and one translational biologist. Using AI models that can predict molecular behavior, they screened 90 different candidate molecules in six months, focusing specifically on compounds that could penetrate the brain barrier needed to treat glioblastoma.

Traditional drug discovery requires testing thousands of molecules one by one in laboratories, a painstaking process that burns through years and resources. The AI platform designed molecules digitally first, predicting which ones would work before ever synthesizing them in a lab.

H.E. Dr. Fatima Al Kaabi, Director General of the Emirates Drug Establishment, emphasized that this achievement goes beyond creating new treatments. It demonstrates the country's growing ability to develop medicines locally using advanced technologies that turn data into faster, more accurate development decisions.

The program launched in May 2025 as an ambitious pilot to prove that generative AI could compress years of traditional research into months. The team met aggressive benchmarks: finalizing their target by late 2025, generating promising molecular structures in under 30 days, and completing lead optimization in less than six months.

The Ripple Effect

This breakthrough reshapes what pharmaceutical innovation can look like globally. Countries without century-old research institutions can now build sovereign capabilities in drug development, potentially bringing treatments to market faster and at lower costs.

For patients with glioblastoma, who currently face limited treatment options and poor survival rates, ISM0387 offers new hope. The drug's enhanced ability to cross the blood-brain barrier addresses one of the biggest challenges in treating brain cancers.

The success also validates the UAE's investment in becoming a knowledge-based economy. Supported by the Abu Dhabi Investment Office and the Department of Health, the initiative demonstrates how strategic partnerships between government, regulators, and biotech companies can accelerate scientific progress.

Minister of State Saeed bin Mubarak Al Hajeri noted that this achievement strengthens the UAE's position in global biotech value chains. The country is building capabilities that allow it to be an active partner in developing pharmaceutical solutions, not just a consumer of medicines developed elsewhere.

The nomination of ISM0387 is Insilico's 30th AI-supported preclinical candidate to date, but the first developed entirely outside traditional pharmaceutical powerhouses. As AI continues to democratize drug discovery, more nations may soon join the race to develop life-saving treatments, turning what was once a "game for the brave" into a globally accessible pursuit that could benefit patients everywhere.